Search research articles
Contact Us
Filters
Showing results (1-10 of 93) with videos related to
Page
of 10
Sort By:
Clinical Chemistry and Laboratory Medicine
|
January 11, 2003
Family studies: their role in the evaluation of genetic cardiovascular risk factors
Marianne Mansour-Chemaly, Nadia Haddy, Gérard Siest, et al.
Journal of the American Heart Association
|
December 19, 2022
<i>N</i>-nitrosodimethylamine-Contaminated Valsartan and Risk of Cancer: A Nationwide Study of 1.4 Million Valsartan Users
Imène Mansouri, Jeremie Botton, Laura Semenzato, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
March 3, 2026
Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer: A Nationwide Cohort Study in France
Allison Singier, Stéphane Vignot, David Desplas, et al.
Clinical and Translational Gastroenterology
|
October 7, 2024
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study
Hugo Jourdain, Nicolas Albin, Adrien Monard, et al.
Atherosclerosis
|
March 17, 2004
Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study
Anne Ponthieux, Bernard Herbeth, Suzanne Droesch, et al.
The Lancet Regional Health. Europe
|
October 27, 2025
PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study
Hugo Jourdain, Nicolas Albin, Adrien Monard, et al.
The Lancet Regional Health. Europe
|
September 24, 2025
Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies
Hugo Jourdain, Antonio Di Meglio, Imène Mansouri, et al.
British Journal of Cancer
|
February 5, 2026
Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer
Aya Elhusseiny Shaaban, Hugo Jourdain, David Desplas, et al.
Atherosclerosis
|
November 13, 2003
IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort
Nadia Haddy, Catherine Sass, Suzanne Droesch, et al.
European Journal of Human Genetics : EJHG
|
November 4, 2004
Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort
Nadia Haddy, Catherine Sass, Sandy Maumus, et al.
Page
of 10
Search research articles
Search
Showing results (1-10 of 93) with videos related to
Sort By:
Page
of 10
Clinical Chemistry and Laboratory Medicine
|
January 11, 2003
Family studies: their role in the evaluation of genetic cardiovascular risk factors
Marianne Mansour-Chemaly, Nadia Haddy, Gérard Siest, et al.
Journal of the American Heart Association
|
December 19, 2022
<i>N</i>-nitrosodimethylamine-Contaminated Valsartan and Risk of Cancer: A Nationwide Study of 1.4 Million Valsartan Users
Imène Mansouri, Jeremie Botton, Laura Semenzato, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
March 3, 2026
Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer: A Nationwide Cohort Study in France
Allison Singier, Stéphane Vignot, David Desplas, et al.
Clinical and Translational Gastroenterology
|
October 7, 2024
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study
Hugo Jourdain, Nicolas Albin, Adrien Monard, et al.
Atherosclerosis
|
March 17, 2004
Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study
Anne Ponthieux, Bernard Herbeth, Suzanne Droesch, et al.
The Lancet Regional Health. Europe
|
October 27, 2025
PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study
Hugo Jourdain, Nicolas Albin, Adrien Monard, et al.
The Lancet Regional Health. Europe
|
September 24, 2025
Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies
Hugo Jourdain, Antonio Di Meglio, Imène Mansouri, et al.
British Journal of Cancer
|
February 5, 2026
Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer
Aya Elhusseiny Shaaban, Hugo Jourdain, David Desplas, et al.
Atherosclerosis
|
November 13, 2003
IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort
Nadia Haddy, Catherine Sass, Suzanne Droesch, et al.
European Journal of Human Genetics : EJHG
|
November 4, 2004
Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort
Nadia Haddy, Catherine Sass, Sandy Maumus, et al.
Page
of 10